Last reviewed · How we verify
Ceclor (CEFACLOR)
Ceclor (cefaclor) is a marketed antibiotic primarily indicated for acute Moraxella catarrhalis bronchitis, with a key composition patent expiring in 2028. Its mechanism of action, inhibiting bacterial cell wall synthesis, provides a robust therapeutic effect against targeted pathogens. The primary risk is the competitive landscape, with multiple off-patent generics of same-class drugs such as cefoxitin, cefuroxime, cefotetan, and cefonicid already available in the market.
At a glance
| Generic name | CEFACLOR |
|---|---|
| Sponsor | Lilly |
| Drug class | cefaclor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
- Acute Moraxella catarrhalis bronchitis
- Acute bacterial bronchitis
- Haemophilus Influenzae Bronchitis
- Haemophilus Influenzae Chronic Bronchitis
- Haemophilus influenzae pneumonia
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
- Infective otitis media
- Lower respiratory tract infection
- Moraxella Catarrhalis Chronic Bronchitis
- Pharyngitis
- Pneumonia
- Pneumonia due to Streptococcus
- Streptococcal tonsillitis
- Streptococcus Pneumoniae Bronchitis
- Streptococcus Pneumoniae Chronic Bronchitis
- Streptococcus pyogenes infection
- Tonsillitis
- Upper respiratory infection
- Urinary tract infectious disease
Common side effects
- Drug hypersensitivity
- International normalised ratio fluctuation
- Cross sensitivity reaction
- Type IV hypersensitivity reaction
- Bloody discharge
- Lyme disease
- Therapeutic product effect incomplete
- Rash maculo-papular
- Infection
- Drug intolerance
- Oedema
- Iron deficiency
Key clinical trials
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- German Corneal Cross Linking Register
- Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy (NA)
- LED Therapy for Third Molar Surgery (EARLY_PHASE1)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- The Effects of Antibiotic Combinations on Stem Cells
- Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |